Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ICG-001 |
Synonyms | |
Therapy Description |
ICG-001 disrupts the interaction of CTNNB1 and c-AMP response element-binding protein, thereby preventing downstream CTNNB1 signaling to promote apoptosis (PMID: 15314234, PMID: 29332125, PMID: 32642722). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ICG-001 | ICG001|ICG 001 | CTNNB1 Inhibitor 27 | ICG-001 disrupts the interaction of CTNNB1 and c-AMP response element-binding protein, thereby preventing downstream CTNNB1 signaling to promote apoptosis (PMID: 15314234, PMID: 29332125, PMID: 32642722). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
APC inact mut | colon cancer | sensitive | ICG-001 | Preclinical | Actionable | In a preclinical study, ICG-001 decreased cell proliferation in colon cancer cell lines and in mouse models carrying APC inactivating mutations (PMID: 15314234). | 15314234 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|